Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net

Intangibles, net

6 Months Ended

Jun. 30, 2019

Intangibles, net

Intangibles, net

9. Intangibles, net

The table below provides a summary of the JMC intangible asset as of June 30, 2019 and December 31, 2018, respectively:


	Estmated Useful	June 30,		December 31,
($ in thousands)	Lives (Years)	2019		2018
		(Unaudited)
Ceracade®	3	$	300	$	300
Luxamend®	3		50		50
Targadox®	3		1,250		1,250
Exelderm®	3		1,200		1,200
Total			2,800		2,800
Accumulated amortization			(1,829)		(1,383)
Net intangible assets		$	971	$	1,417

The table below provides a summary for the six months ended June 30, 2019, of JMC recognized expense related to its product licenses, which was recorded in costs of goods sold on the Condensed Consolidated Statement of Operations:


	Intangible
($ in thousands)	Assets
Beginning balance at January 1, 2019	$	1,417
Amortization expense		(446)
Ending balance at June 30, 2019	$	971

The future amortization of these intangible assets is as follows:


					Total
($ in thousands)	Targadox®		Exelderm®		Amortization
For the six-months ending December 31, 2019	$	104	$	200	$	304
December 31, 2020		—		400		400
December 31, 2021		—		267		267
Total	$	104	$	867	$	971